Improving CAR T cell therapy for acute myeloid leukemia by reducing side effects
NOT-gated CAR T cells to overcome on-target, off-tumor toxicity in AML
This study is looking at a new way to make CAR T cell therapy safer and more effective for people with acute myeloid leukemia (AML) by creating special CAR T cells that can better protect healthy tissues while still fighting the cancer.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10865025 on NIH RePORTER |
What this research studies
This research focuses on enhancing CAR T cell therapy for patients with acute myeloid leukemia (AML) by developing a new type of CAR T cell that minimizes damage to healthy tissues. The approach involves engineering inhibitory CARs (iCARs) that can modulate the activation signals of CAR T cells, thereby reducing harmful side effects while maintaining their effectiveness against leukemia cells. The study will explore optimal designs for these iCARs and investigate how they can interrupt harmful signaling pathways in CAR T cells. This innovative strategy aims to make CAR T cell therapy safer and more effective for AML patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are seeking advanced treatment options.
Not a fit: Patients with other types of leukemia or those who are not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer CAR T cell therapies that improve survival rates for patients with acute myeloid leukemia.
How similar studies have performed: Other research has shown promise in using modified CAR T cells to reduce side effects in different cancers, suggesting potential for success in this novel approach for AML.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Richards, Rebecca Margaret — University of Wisconsin-Madison
- Study coordinator: Richards, Rebecca Margaret
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.